Key facts
- Cajal Therapeutics’s last known valuation is $139.0M (Feb 2025).
- It has raised $135.7M; the latest was Later Stage VC ($40.0M) in Feb 2025.
- Notable investors include Lux Capital, Alexandria Venture Investments, Dolby Family Ventures, Two Sigma Ventures, Bristol-Myers Squibb — 9 tracked in total.
- Status: Privately Held (backing).
Leadership
- Ian PeikonCo-Founder & Co-Chief Executive Officer
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Cajal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cajal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cajal Therapeutics
Developer of disease-altering therapies designed for the treatment of neurodegenerative diseases. The company creates viral tools and platforms to screen for the targets with functional impact on neurodegenerative disease progression as well as offers functional genetic screening and multi-omics approaches to develop precision medicine, enabling healthcare professionals to treat patients with neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 38
- Website
- cajal-tx.com/
- Ownership
- Privately Held (backing)
Cajal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cajal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cajal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.